Objective To investigate clinical efficacy of epirubicin joint docetaxel for triple -negative and non -triple -negative breast cancer,to provide reference for clinical treatment.Methods A retrospective analysis of 80 cases with breast cancer was conducted,26 patients with triple -negative breast cancer were set as study group, and 54 patients with non -triple negative breast cancer were set as control group.All patients used epirubicin docetax-el chemotherapy,the curative effect,survival rate,toxicity were compared between the two groups.Results The chemotherapy response rate of triple -negative breast cancer group was 84.62%,which was significantly higher than 53.70% in non -triple -negative breast cancer group (χ2 =6.45,P <0.01).The 5 -year disease -free survival rate,overall survival rate of triple -negative breast cancer group were 50.00%,73.08%,which were significantly lower than those of non -triple -negative breast cancer group (χ2 =5.89,P <0.01;χ2 =4.19,P <0.01).The inci-dence rates of constipation,nausea,vomiting,leukopenia,neutropenia Ⅲ -Ⅳ degrees reaction were 13.75%, 10.00%,15.00%,13.75%,and the overall incidence rates were 41.25%,42.50%,41.25%,43.75% respective-ly.Conclusion Epirubicin joint docetaxel adjuvant chemotherapy has good short term efficacy for triple negative breast cancer,but its long -term efficacy is poor to non -triple -negative breast cancer.